Sankaran Naren favours banks, power as oil risks loom
Sankaran Naren, CIO of ICICI Prudential Asset Management, remains bullish on banks, power utilities, oil refiners and pharmaceuticals, citing attractive valuations and improving earnings despite global uncertainties. He cautioned that a sharp rise...

Attractive valuations for lenders, along with rising demand for power infrastructure and healthcare, make the sectors compelling investment opportunities, according to Sankaran Naren, chief investment officer of ICICI Prudential Asset Management Co., which has about 11.8 trillion rupees ($123 billion) in assets, with equities making up over two-thirds of the total.
“Banking remains one of the most attractive sectors in India,” he said in an interview on Wednesday.

The remarks from Naren, one of India’s longest-serving fund managers who popularised contra and value investing in the country, come as corporate earnings show signs of recovery. Materials, utilities and financial services have led the turnaround, with more than half of the 34 NSE Nifty 50 companies that have reported June-quarter results beating profit estimates, data compiled by Bloomberg show.
The improving earnings outlook has helped put the benchmark Nifty on track for a second month of gains. The advance has also been assisted by a revival in foreign inflows and a recovery in the nation’s beaten-down software stocks as investors rotate out of chip shares elsewhere in Asia. But the spike in Brent crude prices above $90 a barrel poses a risk to the recovery, Naren said.
Reflecting that view, Naren’s $9 billion ICICI Prudential Multi Asset Fund, which has beaten 95% of peers over five years, remains overweight on lenders and has added Kotak Mahindra Bank, HDFC Bank and Union Bank of India in recent months.
“Prolonged foreign selling has left many large-caps trading at appealing multiples,” he said.
Global funds dumped $6.5 billion of financials shares in March as part of their broader exodus from Indian equities, pushing the NSE Nifty Bank index close to bear-market territory. The measure has since rebounded more than 13% but still trades at nearly a 20% discount to its long-term price-to-book value, data compiled by Bloomberg show.
“Pharma has consistently delivered for us. We continue to find the sector attractive,” he said.
Download ET Markets APP